Stocks / NASDAQ / Coherus BioSciences, Inc.

Coherus BioSciences, Inc.

Our Opinion

Coherus BioSciences, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.

Supporting Evidence:

The following report cites that the company tests their products on animals to assess a product’s safety profile.

“Complete additional animal studies on CHS-131 to further validate its mechanism of action, pursuant to a licensing agreement in the second half of 2017. ” Read the full document.

Company Description

Coherus BioSciences, Inc. engages in the development and commercializition of biosimilar therapeutics worldwide. Its clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor, a substance in the body that is involved in the inflammatory response; and a long-acting form of granulocyte colony-stimulating factor, a beneficial substance in the body that stimulates production of granulocytes (a type of white blood cell) in order to promote the body’s ability to fight infections. The company was founded by Dennis M. Lanfear and Stuart E. Builder in September 2010 and is headquartered in Redwood City, CA. [Source: MarketWatch]

Company Website: